Efficacy and tolerance of betamethasone dipropionate propylene glycol for resistant psoriasis and other resistant steroid-responsive dermatoses.

Betamethasone dipropionate, 0.05%, in a propylene glycol ointment vehicle (Diprolene Ointment) was administered to forty-seven patients with resistant psoriasis or other resistant steroid-responsive dermatoses in a 2 week open study. The efficacy and tolerance of this new topical corticosteroid preparation were evaluated. Response was rapid, as illustrated by the sharp decrease in the severity of signs and symptoms. All patients improved. Lesions cleared in 25.5% of cases (twelve patients), showed marked improvement in 66% (thirty-one patients) and showed moderate improvement in 8.5% (four patients). Six patients developed folliculitis which did not necessitate discontinuation of Diprolene therapy. No changes in adrenal function were detected.

[Oral tuberculosis (report of 2 cases)]. / Tuberculosis oral (presentación de dos casos)

Two cases are hereby presented, diagnosed through clinical, laboratory radiology and histological methods. In each case, the oral involvement was associated with pulmonary tuberculosis. The trauma, particularey in the teeth, is an important deciding factor. Clinically, some ulcerous lesions in mucous membranes and tongue were observed, with definite characteristics such as quite severe pain, difficulty in swallowing and talking. The selected treatment has been chemical therapy. Looking back at hospital files, these two cases have been the only ones observed at Hospital de San Jaun de Dios of Bogotá, in the last fifteen years.

Eficacia y tolerancia del dipropionato de betametasona glicol de propileno para la psoriasis resistente y otras dermatosis resistentes que responden a corticoterapia. / Efficacy and tolerance of betamethasone dipropionate propylene glycol for resistant psoriasis and other resistant steroid-responsive dermatosis

Se administro dipropionato de betametasona al 0.05% en unguento con un vehiculo de glicol de propileno a 47 enfermos con psoriasis u otras dermatosis resistentes, susceptibles a la corticoterapia, en un estudio de diseno abierto, de dos semanas de duracion. Se evaluo la eficacia y tolerancia de esta nueva preparacion corticosteroidea topica. La respuesta fue rapida, como queda ilustrado por la disminucion abrupta de la severidad de los signos y sintomas. Todos los enfermos mejoraron.Las lesiones desaparecieron en 25.5% (12 pacientes), mostraron mejoria notable en 66% (31) y mejoria moderada en 8.5% (4) de los enfermos. Seis pacientes desarrollaron foliculitis que no requirio la suspension del tratamiento. No se descubrieron cambios en la funcion suprarrenal